Dedicare AB (DEDI) AI Stock Analysis

• Market Cap: kr470.48M
• Dividend Yield: 5.48%
• Average Volume (3M): 12.35K
• Price to Earnings (P/E): 12.6
• Beta (1Y): -0.03
• Revenue Growth: -16.43%
• EPS Growth: -57.84%
• Country: SE
• Employees: 904
• Sector: Healthcare
• Sector Strength: 49
• Industry: Staffing & Employment Services
• EPS (TTM): 0.95
• Shares Outstanding: 7,550,735
• 10 Day Avg. Volume: 11,095
• 30 Day Avg. Volume: 12,345
• PEG Ratio: -0.20
• Price to Book (P/B): 1.81
• Price to Sales (P/S): 0.32
• P/FCF Ratio: 6.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr53.00
• Price Target Upside: 7.72% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 77 Outperform
• Price Target: kr53.00 ▲(7.72% Upside)

Dedicare AB's strong financial performance and attractive valuation are the primary drivers of its score. The company's robust cash flow and low leverage provide a solid foundation, while its undervalued P/E ratio and high dividend yield enhance its investment appeal. Technical analysis indicates positive short-term trends, though some caution is warranted due to long-term resistance.

Dedicare AB Business Overview & Revenue Model

Company Description

Dedicare AB (DEDI) is a leading staffing company based in Sweden, specializing in the recruitment and placement of healthcare professionals. The company operates primarily in the Nordic region, providing temporary and permanent staffing solutions to hospitals, healthcare institutions, and social services. Dedicare's core services include the recruitment and assignment of nurses, doctors, and other healthcare professionals, addressing the growing demand for skilled personnel in the healthcare sector.

How the Company Makes Money

Dedicare AB generates revenue primarily through the provision of staffing services to the healthcare industry. The company charges healthcare institutions and organizations for supplying qualified healthcare professionals on both a temporary and permanent basis. Revenue streams include fees for recruitment services, hourly rates for temporary staffing assignments, and placement fees for permanent hires. Dedicare leverages its extensive network of healthcare professionals and its reputation for quality and reliability to secure contracts with hospitals, clinics, and other healthcare providers. Additionally, the company may benefit from partnerships with public and private healthcare organizations, contributing to its earnings through long-term contracts and repeat business.

Dedicare AB Financial Statement Overview

Summary

Dedicare AB displays a strong financial profile characterized by robust cash flow, stable growth, and a secure balance sheet. While recent revenue and net income have faced pressures, the company's solid margins and low leverage position it well for future resilience.

Income Statement

The company has shown consistent revenue growth over the years, although there was a decline in 2024. Gross profit margins have been relatively stable, indicating efficient cost management. Net profit margin decreased in 2024, reflecting some challenges in maintaining profitability levels. The EBIT and EBITDA margins have been solid, pointing to strong operational performance.

Balance Sheet

Dedicare AB maintains a strong equity position with a healthy equity ratio, indicating financial stability. The debt-to-equity ratio is low, suggesting prudent financial management and low leverage risk. Return on equity remains attractive, showcasing effective use of shareholder funds.

Cash Flow

Operating cash flow remains robust and consistently exceeds net income, demonstrating strong cash generation. Free cash flow growth has been positive, although it decreased in the latest period. The ratios of operating and free cash flow to net income indicate efficient cash management relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.55B	1.72B	1.97B	1.77B	1.25B	885.20M
Gross Profit	237.30M	444.92M	351.50M	529.42M	337.40M	125.52M
EBITDA	69.70M	89.34M	171.42M	154.37M	102.31M	61.38M
Net Income	37.30M	47.07M	110.40M	101.30M	65.56M	36.06M
Balance Sheet
Total Assets	568.00M	628.76M	727.32M	742.68M	497.86M	384.61M
Cash, Cash Equivalents and Short-Term Investments	95.00M	115.26M	187.15M	142.80M	132.43M	100.29M
Total Debt	22.30M	38.05M	87.96M	116.01M	33.55M	40.92M
Total Liabilities	285.40M	329.46M	417.39M	480.13M	319.37M	249.19M
Stockholders Equity	282.60M	299.30M	309.93M	262.56M	178.49M	135.42M
Cash Flow
Free Cash Flow	63.00M	78.03M	140.85M	99.97M	67.30M	37.54M
Operating Cash Flow	64.60M	81.28M	145.40M	105.34M	69.59M	40.10M
Investing Cash Flow	-37.80M	-39.47M	-9.67M	-68.61M	-2.29M	-26.47M
Financing Cash Flow	-57.90M	-88.19M	-81.83M	-30.07M	-36.74M	25.80M

Dedicare AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 49.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:DEDI, the sentiment is Positive. The current price of 49.2 is above the 20-day moving average (MA) of 46.46, above the 50-day MA of 45.93, and below the 200-day MA of 49.21, indicating a neutral trend. The MACD of 1.01 indicates Negative momentum. The RSI at 66.06 is Neutral, neither overbought nor oversold. The STOCH value of 78.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:DEDI.

Dedicare AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DEDI	77 Outperform	kr470.48M	12.58		5.48%	-16.43%	-57.84%
INTEG.B	62 Neutral	kr898.18M	―	-19.17%	―	-12.50%	-783.92%
Sector *	51 Neutral	kr6.00B	8.76	-28.73%	2.23%	51.33%	18.74%
BRAIN	50 Neutral	kr299.00M	―	-26.66%	―	18.37%	34.23%
VICO	45 Neutral	kr2.72B	―	-40.15%	―	-94.25%	9.47%
IRLAB.A	38 Underperform	kr261.37M	―	-194.31%	―	1643.36%	50.36%
CANTA	31 Underperform	kr723.46M	―	-167.55%	―	―	37.89%